Wang, N.; Fu, J.; Li, Z.; Jiang, N.; Chen, Y.; Peng, J. The Landscape of PDK1 in Breast Cancer. Cancers 2022, 14, 811, doi:10.3390/cancers14030811.
Wang, N.; Fu, J.; Li, Z.; Jiang, N.; Chen, Y.; Peng, J. The Landscape of PDK1 in Breast Cancer. Cancers 2022, 14, 811, doi:10.3390/cancers14030811.
Wang, N.; Fu, J.; Li, Z.; Jiang, N.; Chen, Y.; Peng, J. The Landscape of PDK1 in Breast Cancer. Cancers 2022, 14, 811, doi:10.3390/cancers14030811.
Wang, N.; Fu, J.; Li, Z.; Jiang, N.; Chen, Y.; Peng, J. The Landscape of PDK1 in Breast Cancer. Cancers 2022, 14, 811, doi:10.3390/cancers14030811.
Abstract
Given that 3-Phosphoinositide-dependent kinase 1 (PDK1) plays a crucial role in malignant biological behaviors of a wide-range of cancers, we further review the influence of PDK1 in breast cancer (BC). First, we describe the power of PDK1 in cellular behaviors and extensively demonstrate the interacting networks of PDK1 via PI3K-dependent/ PI3K-independent pathway. Then we enlighten the roles of PDK1 in carcinogenesis, growth and survival, metastasis, and chemoresistance in BC cells. More important, we sort the current preclinical or clinical trials of PDK1 targeted therapy in BC and find that even though at present no selective PDK1 inhibitor is available for BC therapy, but the combination trials of PDK1 targeted therapy and other agents have demonstrated some benefit. Thus, there is increasing anticipations that PDK1 targeted therapy will have its space in future therapeutic concepts of BC, and we hope to feature PDK1 in BC to the clinic and bring the new promising to patients for targeted therapies.
Keywords
PDK1; breast cancer; survival; prognosis; targeted therapy
Subject
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.